[Form 4] GeneDx Holdings Corp. Insider Trading Activity
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Feeley Kevin
Role
CHIEF FINANCIAL OFFICER
Sold
388 shs ($41K)
Approx. gross sale proceeds
$41K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 753 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 753 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 388 | $105.31 | $41K |
Holdings After Transaction:
Restricted Stock Unit — 2,261 contracts (Direct);
Class A Common Stock — 3,757 shares (Direct)
Footnotes (4)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- F2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- F3. Following the reported sales, in addition to the 3,757 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 135,009 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms.
- F4. 25% of the total RSUs vest on April 29, 2023 and April 29, 2024, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested on April 29, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.